William Conkling - 25 Mar 2025 Form 4 Insider Report for Rafael Holdings, Inc. (RFL)

Role
Chief Executive Officer
Signature
Joyce J. Mason, by Power of Attorney
Issuer symbol
RFL
Transactions as of
25 Mar 2025
Net transactions value
$0
Form type
4
Filing time
24 Apr 2025, 15:18:53 UTC
Previous filing
25 Mar 2025
Next filing
04 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RFL Class B Common Stock, par value $.01 per share Award +27,454 +5.1% 564,455 25 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RFL Employee Stock Option (right to buy) Award +2,362 2,362 25 Mar 2025 Class B Common Stock 2,362 $3.89 Direct F3
transaction RFL Employee Stock Option (right to buy) Award +5,485 5,485 25 Mar 2025 Class B Common Stock 5,485 $3.63 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person received these shares in exchange for 77,884 shares of Cyclo Therapeutics, Inc. ("Cyclo") common stock in connection with the business combination between Cyclo and the Issuer (the "Merger") based upon an exchange ratio of 0.3525.
F2 Consists of 174,409 shares of stock held directly, 183,094 fully vested shares of Restricted Stock and 206,952 shares of unvested Restricted Stock that vest as follows: 38,983 shares to vest quarterly, June 21, 2025 through September 21, 2025, and 38,986 shares to vest on December 21, 2025; 10,000 shares to vest on each of October 25, 2025, October 25, 2026 and October 25, 2027; and 15,000 shares to vest on each of January 13, 2026, January 13, 2027, January 13, 2028 and January 13, 2029.
F3 The Reporting Person received this option to purchase shares of stock in the Merger in exchange for an employee stock option granted to Mr. Conkling on June 6, 2023 to purchase 6,700 shares of Cyclo common stock at an exercise price of $1.37.
F4 The Reporting Person received this option to purchase shares of stock in the Merger in exchange for an employee stock option granted to Mr. Conkling on June 3, 2024 to purchase 15,562 shares of Cyclo common stock at an exercise price of $1.28.